| Q37146276 | 2015 Russell Ross Memorial Lecture in Vascular Biology: Protective Autoimmunity in Atherosclerosis |
| Q34416243 | A journey in science: medical scientist in translation |
| Q36186394 | Ablation of CD8α(+) dendritic cell mediated cross-presentation does not impact atherosclerosis in hyperlipidemic mice |
| Q55265513 | Activation of the Regulatory T-Cell/Indoleamine 2,3-Dioxygenase Axis Reduces Vascular Inflammation and Atherosclerosis in Hyperlipidemic Mice. |
| Q36497196 | Adaptive immunity in atherogenesis: new insights and therapeutic approaches |
| Q34238712 | Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprotective vaccine |
| Q46473311 | Atheroprotective vaccination with MHC-II-restricted ApoB peptides induces peritoneal IL-10-producing CD4 T cells |
| Q37953777 | Atherosclerosis: current pathogenesis and therapeutic options |
| Q36079808 | Beyond vascular inflammation--recent advances in understanding atherosclerosis |
| Q36686150 | Comprehensive insight into immune regulatory mechanisms and vascular wall determinants of atherogenesis - emerging perspectives of immunomodulation |
| Q39193752 | Dendritic Cell KLF2 Expression Regulates T Cell Activation and Proatherogenic Immune Responses |
| Q98735442 | Dendritic Cells and T Cells, Partners in Atherogenesis and the Translating Road Ahead |
| Q38023274 | Dendritic cells and regulatory T cells in atherosclerosis |
| Q37624571 | Dendritic cells in atherosclerosis |
| Q38218096 | Dendritic cells in atherosclerotic inflammation: the complexity of functions and the peculiarities of pathophysiological effects |
| Q38078691 | Dendritic cells: an important link between antiphospholipid antibodies, endothelial dysfunction, and atherosclerosis in autoimmune and non-autoimmune diseases |
| Q36366126 | Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models |
| Q37661552 | Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome. |
| Q26994661 | Fibrocalcific aortic valve disease: opportunity to understand disease mechanisms using mouse models |
| Q37150605 | Immune effector mechanisms implicated in atherosclerosis: from mice to humans |
| Q35599691 | Immune modulation of atherosclerosis |
| Q38083555 | Inflammation and immune system interactions in atherosclerosis |
| Q37370224 | Inflammation and plaque vulnerability |
| Q37556429 | Interleukin-37 and Dendritic Cells Treated With Interleukin-37 Plus Troponin I Ameliorate Cardiac Remodeling After Myocardial Infarction |
| Q35121259 | Left ventricular dysfunction with reduced functional cardiac reserve in diabetic and non-diabetic LDL-receptor deficient apolipoprotein B100-only mice |
| Q35713532 | Linking immunity to atherosclerosis: implications for vascular pharmacology--a tribute to Göran K. Hansson |
| Q35597306 | MHC Class II-restricted antigen presentation by plasmacytoid dendritic cells drives proatherogenic T cell immunity |
| Q61449503 | Macrophage Foam Cell-Targeting Immunization Attenuates Atherosclerosis |
| Q38205771 | Metabolic syndrome - Removing roadblocks to therapy: Antigenic immunotherapies |
| Q35591762 | Modulation of recombinant antigenic constructs containing multi-epitopes towards effective reduction of atherosclerotic lesion in B6;129S-Ldlr(tm1Her)Apob(tm2Sgy)/J mice |
| Q37254899 | Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes |
| Q26822962 | Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis |
| Q36064574 | Plasmacytoid dendritic cells in atherosclerosis |
| Q49603124 | Potential of anti-inflammatory agents for treatment of atherosclerosis |
| Q92753286 | Proinflammatory Action of a New Electronegative Low-Density Lipoprotein Epitope |
| Q94569710 | Reformulating Small Molecules for Cardiovascular Disease Immune Intervention: Low-Dose Combined Vitamin D/Dexamethasone Promotes IL-10 Production and Atheroprotection in Dyslipidemic Mice |
| Q47314271 | Regulation of pro- and anti-atherogenic cytokines |
| Q38620803 | Regulatory T cells in atherosclerosis: critical immune regulatory function and therapeutic potential. |
| Q28553042 | Simvastatin Efficiently Lowers Small LDL-IgG Immune Complex Levels: A Therapeutic Quality beyond the Lipid-Lowering Effect |
| Q28396774 | T cell costimulatory and coinhibitory pathways in vascular inflammatory diseases |
| Q26740179 | Targeting T cells to treat atherosclerosis: odyssey from bench to bedside |
| Q35550211 | The autoimmune concept of atherosclerosis |
| Q34164644 | The immune system in atherosclerosis |
| Q39230390 | The immunology of atherosclerosis |
| Q27000370 | The influence of innate and adaptive immune responses on atherosclerosis |
| Q37050929 | The role of the vascular dendritic cell network in atherosclerosis |
| Q37328817 | Thymic stromal lymphopoietin attenuates the development of atherosclerosis in ApoE-/- mice |
| Q92132636 | Tolerogenic Dendritic Cells Reduce Cardiac Inflammation and Fibrosis in Chronic Chagas Disease |
| Q38270134 | Treating atherosclerosis with regulatory T cells |
| Q36497238 | Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs. |
| Q35600876 | Vaccination to modulate atherosclerosis |
| Q92287764 | [Immunity and inflammation in atherosclerosis] |
| Q36302743 | microRNA-181a represses ox-LDL-stimulated inflammatory response in dendritic cell by targeting c-Fos |